Mouse Myeloperoxidase MPO ELISA Kit

Kit Components

 1. Recombinant Mouse MPO standard: 2 vials.

 2. One 96-well plate precoated with anti- Mouse MPO Ab

 3. Sample diluent buffer: 12 mL - 1

 4. Detection antibody: 130 µL, dilution 1:100.

 5. Streptavidin-HRP: 130 µL, dilution 1:100

 6. Antibody diluent buffer: 12 mL x1

 7. Streptavidin-HRP diluent buffer: 12 mL x1

 8. TMB developing agent: 10 mL x1

9. Stop solution: 10 mL x1.

10. Washing solution (20x): 25 mL x1.

Background

Myeloperoxidase (MPO) is a heme-containing enzyme belonging to the XPO subfamily of peroxidases. MPO is synthesized as a preproprotein that generates separate 60 kDa heavy and 12 kDa light chains by removing a 48 amino acid (aa) signal peptide, a 116 aa propeptide, the C-terminal serine, and a 6 aa internal peptide via proteolytic processing. The active form of MPO is a disulfide-linked tetramer that contains two heme groups and two copies of the heavy and light chains. Mouse and human MPO share 87% aa sequence identity. MPO binds albumin, the macrophage mannose receptor, cytokeratin 1 on vascular endothelial cells, high molecular weight kininogen, and the integrin CD11b/CD18 on neutrophils. Neutrophil MPO is stored in cytoplasmic azurophilic granules. Upon cellular activation and degranulation, MPO is delivered into phagosomes where it is required for the killing of phagocytosed bacteria. Activated neutrophils also release granule contents extracellularly. These interactions promote MPO clearance, a reduction of nitric oxide and bradykinin levels, reduced vasodilation, and continued neutrophil activation. Elevated plasma MPO levels have been associated with a variety of pathological conditions including systemic inflammation, eclampsia, vascular endothelial dysfunction, severity of multiple sclerosis, and prospective mortality and oxidative stress during hemodialysis.